Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SHCN4KCNJ2SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Dronedarone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronedarone SCHEMBL4540209 | 1.00 | ESR1 (1.00) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL29533002 | 1.00 | ESR1 (1.00) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL18074257 | 0.99 | ABCB11 (1.00) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL223035 | 0.99 | ABCB11 (1.00) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL2472589 | 0.99 | ESR1 (0.98) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL29620421 | 0.99 | ABCB11 (1.00) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL321382 | 0.99 | ESR1 (0.98) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL28179052 | 0.99 | ESR1 (0.98) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL322530 | 0.98 | ABCB11 (0.98) | ESR1PGRCHRM2HTR1AADRA2A | |
| Dronedarone SCHEMBL22527644 | 0.98 | ESR1 (0.97) | ESR1PGRCHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5000 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-03-05 | — | — | US | claimed |
| US-12544338-B2 | Solid or semisolid lipid based dosage form stabilization through curing and addition of low HLB surfactant(s) | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-01-29 | — | — | US | claimed |
| US-12533358-B1 | Methods of treatment with elinzanetant | BAYER CONSUMER CARE AG (CH) | 2026-01-27 | — | — | US | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-1007030-A1 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURANE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-06-14 | — | — | EP | claimed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5985915-A | CARDIOVASCULAR DISORDERS SUCH AS ARRHYTHMIA | SANOFI (FR) | 1999-11-16 | — | — | US | claimed |
| CN-1213965-A | Use of antiarrhythmic compounds for reducing post-infarction morality | SANOFI SA (FR) | 1999-04-14 | — | — | CN | claimed |
| WO-1998058643-A1 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURANE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 1998-12-30 | — | — | WO | claimed |
| WO-1998040067-A1 | USE OF BENZOFURAN DERIVATIVES FOR REDUCING DEATH RATE AFTER MYOCARDIAL INFARCTION | SANOFI (FR) | 1998-09-17 | — | — | WO | claimed |
| WO-1997034597-A1 | USE OF ANTIARRHYTHMIC COMPOUNDS FOR REDUCING POST-INFARCTION MORTALITY | SANOFI (FR) | 1997-09-25 | — | — | WO | claimed |
| EP-0796617-A1 | Use of antiarhythmic compounds to reduce post-infarct mortality | SANOFI (FR) | 1997-09-24 | — | — | EP | claimed |
| EP-0471609-B1 | Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them | SANOFI SA (FR) | 1996-11-27 | — | — | EP | claimed |